C4 Therapeutics Inc (NASDAQ:CCCC) shares are trading significantly lower Friday afternoon after the company presented data from Cohort A of its ongoing Phase 1/2 clinical trial of CFT7455.
Cohort A, the first cohort in the clinical trial, explored CFT7455 as a single agent and enrolled five patients with multiple myeloma. The company said that at the time of the data cut-off, two patients remained on therapy, however, all patients have since discontinued treatment.
